MedPage Today (12/3, Monaco) reports a study found that “low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose schizophrenia was being treated with the second-generation antipsychotics clozapine or olanzapine.” According to researchers, “the 73 randomized study participants all had early-stage metabolic abnormalities, and a once-weekly 1-mg dose of semaglutide significantly reduced HbA1c compared with placebo at week 26.” Furthermore, “more than 40% of the patients assigned to semaglutide achieved a low-risk HbA1c at that point versus 3% of those on placebo.” The researchers noted that after 26 weeks, “the semaglutide group also achieved significant reductions versus the placebo group in body weight (mean difference -20.3 lb), waist circumference (-7.0 cm), and fat mass (-13.4 lb).” The study was published in JAMA Psychiatry.
Related Links:
— MedPage Today (requires login and subscription)